Ibogaine Research Database

Real-world use of classic and non-classic psychedelics in Hispanic/Latino adults with obsessive-compulsive disorder: international findings from the LATINO Study.

Despite growing research on the potential mental health benefits of psychedelics, there has been limited study of these drugs in populations with obsessive-compulsive disorder (OCD) and with Hispanic and Latin American (H/L) ancestry. Demographic and clinical assessments were con...

Differential Impacts of Methadone and Buprenorphine/Naloxone on Pain-Related Outcomes Among People With Non-Heroin Opioid Use Disorder: Secondary Analyses From a Pragmatic Canadian Multisite

In addition to their use as opioid agonist therapy (OAT), methadone and buprenorphine/naloxone also have analgesic properties. However, there is limited information on the relative effectiveness of these medications for analgesia in the context of treatment for non-heroin opioid ...

Development of Bioisosteres of Iboga Alkaloids: A Step-Economical Synthesis to Enhance the Antinociceptive and Anxiolytic Activity with Neuroprotective Effects.

The clinical importance of iboga alkaloids lies in their efficacy in reversing drug addiction and modulating drug tolerance. However, due to safety concerns, their use is restricted to appropriate medical supervision. These alkaloids often cause severe psychedelic effects due to ...

The purpose of the psychosocial protocol in the psychedelic-assisted therapy: A scoping review.

With growing research on the use of psychedelics to treat mental health conditions, greater attention to the psychosocial procedures accompanying substance administration is warranted. This scoping review aims to categorize psychosocial protocols used in research involving psyche...

Tuning reductase activity in monoterpene indole alkaloid biosynthesis.

Monoterpene indole alkaloids encompass a diverse class of plant natural products. Many of these valuable compounds, including the anticancer medicines vinblastine and vincristine (Catharanthus roseus) and the antiaddiction treatment ibogaine (Tabernanthe iboga) utilize a common b...

Psychedelic Modulation of Excitation/Inhibition Balance: A Dual-Phase Neurodevelopmental Model.

Psychedelics are a diverse class of psychoactive compounds that profoundly alter perception, cognition, and emotional states. Recently, classical serotonergic agents, such as psilocybin and lysergic acid diethylamide (LSD), along with atypical agents such as methylenedioxymethamp...

Novel pharmacotherapies for opioid use disorder and opioid withdrawal.

Opioid use disorder (OUD) remains a major public health crisis despite evidence-based medications, including methadone, buprenorphine, and naltrexone. Persistent challenges with treatment retention, access, stigma, and incomplete response highlight the need for adjunctive pharmac...

Clinical improvement following an integrative iboga microdosing protocol in post-concussive and hypoxic brain injury syndromes: a case series.

Traumatic brain injury (TBI) can result in prolonged post-concussive syndrome and chronic hypoxic-ischemic brain injury (HIBI) sequelae remains therapeutically challenging with the persistence of significant neurological and cognitive impairments. While conventional treatments of...

Indole Alkaloids as Biased Opioid Receptor Modulators.

Background: Opioid receptors are a commonly used target for treatment of pain conditions. Most opioids used in therapy are linked to adverse effects such as tolerance, dependence, and respiratory depression. Indole alkaloids acting on opioid receptors may provide a novel molecula...

Oxa-noribogaine reduces alcohol drinking through aversion learning and by altering glutamatergic activity in the mPFC.

Alcohol use disorder is a major global health problem, and current treatments often fail to produce lasting reductions in harmful drinking1,2. Psychedelic-assisted therapies may promote durable behavioural change by enhancing brain plasticity during emotionally meaningful experie...

Efficacy and Safety of Psychoactive Tryptamines in Addiction: A Systematic Review.

Psychedelics such as lysergic acid diethylamide (LSD) and psilocybin have shown a beneficial effect on substance use disorder (SUD) symptoms. In this systematic review, we aimed to assess the efficacy and safety of psychoactive tryptamines in patients with an SUD or non-substance...

Selective Delivery of Anticancer Natural G-Quadruplex Ligands by the AT11 Aptamer for Gastric Cancer Treatment.

Searching for G-quadruplex-selective ligands as anticancer agents, we recently identified the natural compounds bulbocapnine, chelidonine, dicentrine, ibogaine, and rotenone as novel interactors of G-quadruplexes. Herein, to investigate their ability to interact with a specific c...

Psychedelics and Ibogaine "Pain Medications" at the Pharmacy Counter: Implications for Pharmacy Practice.

US speeds up research into mind-altering drugs - including mysterious 'ibogaine'.

Ibogaine in the Vet Brain: Changes in Brain Metabolism and Connectivity After Ibogaine Administration in Veterans With Traumatic Brain Injury.

Accelerated recovery using magnesium ibogaine: characterizing the subjective experience of its rapid healing from neuropsychiatric disorders.

Magnesium-ibogaine, a formulation combining ibogaine with pre- and post-treatment magnesium, was recently found to yield rapid clinical improvements in U.S. Special Operations veterans with TBI and PTSD. Yet, its therapeutic phenomenology during such healing is unknown. We analyz...

Increased cortical thickness and decreased brain age among special operations veterans with blast TBI after a magnesium-ibogaine protocol.

Ibogaine is a psychoactive alkaloid with therapeutic potential that may promote neuroplasticity. Its effects on human brain morphometry are unknown. Thirty Special Operations Forces veterans with prior blast-induced TBI participated in an observational study in which they receive...

Implications of Potential US FDA Approval of Psychedelics or Psychedelic-Adjacents Such as Ibogaine for Pharmacy in Japan.

An Executive Order signed in April 2026 directed US federal agencies to expedite development and review pathways for psychedelic and psychedelic-adjacent (such as ibogaine) therapies. The FDA issued Commissioner's National Priority Vouchers to psilocybin developers, and cleared t...

Development and validation of a UPLC-MS/MS method for real-time neuropharmacokinetic monitoring of iboga alkaloids in rat brain.

Iboga alkaloids, including ibogaine, its primary metabolite noribogaine, and the naturally occurring congener ibogamine, have shown promise for the treatment of substance use and other neuropsychiatric disorders but are limited by cardiotoxic effects. Safer synthetic analogs, suc...

Voacangine/coronaridine hydroxylases catalyze C19-hydroxylation in iboga alkaloid synthesis.

The combination of bioinformatics and functional approaches was used to identify three cytochrome P450 from the CYP71 clan that perform the 19-hydroxylation of two monoterpene indole alkaloids (coronaridine and voacangine) from Voacanga thouarsii.  Voacanga thouarsii is a medicin...

Beyond the Genomic Storm: Evaluating Tabernanthalog as a Potential Scaffold for Silent Neuroplasticity and Broad-Spectrum Therapy.

The clinical renaissance of psychedelic medicine has highlighted the therapeutic potential of rapid-acting neuroplastogens, or "psychoplastogens," for psychiatric disorders. However, the widespread application of classical psychedelics-such as psilocybin and LSD-and the atypical ...

Non-adherence to registration further undermines the methodologically weak Stanford University Magnesium-Ibogaine Study.

From monotherapy to sequential models: An updated scoping review on ibogaine's role in treatment for psychiatric disorders.

Preliminary evidence examining ibogaine in neuropsychiatric and substance use disorders is accumulating. As patient interest and off-label use grow, clinicians require an understanding of emerging dosing strategies, investigational protocols, and reported adverse effects to appro...

Ibogaine as a double-edged sword: Developmental cardiotoxicity and neurobehavioral alterations in zebrafish.

Ibogaine has attracted increasing attention as a potential treatment for substance use disorders; however, its clinical application remains limited by well-documented cardiotoxicity, and its safety during early development is poorly understood. Here, we investigated the developme...

Ibogaine induces juvenile-like plasticity and modulates functional and structural regulators of plasticity in the adult mouse visual cortex.

Psychedelics have emerged as powerful modulators of neural plasticity, yet whether the atypical psychedelic ibogaine can enhance plasticity remains poorly understood. Here, we investigated whether a single administration of ibogaine can reinstate juvenile-like experience-dependen...

Toward a nuanced framework for the medical development of ibogaine and its analogues and derivatives: implications for psychopharmacology.

Ibogaine is a naturally occurring indole alkaloid with suggested therapeutic potential across substance use disorders, trauma-related conditions, mood disorders, and suicidality. However, its clinical translation has been hindered by safety concerns, regulatory barriers, and unce...

Thirty Years of Ibogaine Research: A Literature Review on Clinical Perspectives.

Ibogaine has garnered interest for its potential therapeutic properties in substance use and psychiatric disorders. Unlike classic psychedelics such as psilocybin or LSD, ibogaine remains underexplored in clinical research. This review aimed to synthesize the clinical literature ...

Neurorestorative properties of ibogaine: linking multi-receptor affinities to remyelination and metabolic restoration.

Ibogaine is a psychedelic alkaloid without an approved indication. Observational clinical research shows linkages between single administration of ibogaine and relief of symptoms of neuropsychiatric conditions including substance use disorder, multiple sclerosis (MS), and traumat...

Rare but relevant: Ibogaine and cardiovascular complications-prolonged QT interval and ventricular arrhythmias.

Revived interest in psychedelic-assisted therapies has also renewed focus on ibogaine, a psychoactive alkaloid, for its notable anti-addictive potential. Evidence from observational, open-label, and limited randomized placebo-controlled trials indicates that ibogaine and its meta...

Ibogaine: Therapeutic Potential, Cardiac Safety, and Translational Perspectives in the Treatment of Substance Use Disorders-A Scoping Review.

Substance Use Disorder (SUD) constitutes a major and persistent global public health burden, accounting for approximately 600,000 deaths annually, largely driven by opioid use. Despite substantial advances in addiction neuroscience, currently approved therapeutic strategies remai...

Psilocybin and Ibogaine in Cocaine-Seeking: Extinction Enhancement Without Relapse Prevention.

Psychedelics have emerged as potential therapeutics for substance use disorders, yet preclinical data validating their efficacy remain limited. Here, we investigated the effects of a clinically inspired dose-escalation protocol of psilocybin and ibogaine on extinction and cue-ind...

Neural Correlates of Ibogaine: Evidence From Functional Neuroimaging of Military Veterans.

Ibogaine was recently found to result in significant functional improvements in treating the sequelae of traumatic brain injury (TBI) among Special Operations Forces veterans (SOVs). In the current study, we used multimodal neuroimaging to elucidate the neural correlates of iboga...

Feasibility, safety and preliminary effects of ibogaine in patients with moderate and severe alcohol use disorder: a pilot, open-label study.

Ibogaine is a natural hallucinogen with emerging evidence for treating substance use disorders. However, its cardiovascular effects are not fully known, and most clinical data focus on opioid dependence, with limited data for Alcohol Use Disorder (AUD). This study assessed the fe...

Exploring the Use of Ibogaine in Opioid Recovery: Insights from Lived Experience.

Opioid dependence is a public health concern in New Zealand, with limited treatment options beyond opioid substitution therapy (OST). Ibogaine, a psychoactive alkaloid with reported anti-withdrawal and anti-craving effects for opioid dependence, is legally available by prescripti...

Sustained abstinence in severe ketamine use disorder following ibogaine treatment case report.

Substance use disorders (SUD) involving ketamine, cocaine, and alcohol present significant clinical challenges, often characterized by high relapse rates and limited pharmacological options. This case report details a 30-year-old male with a five-year history of severe polysubsta...

Psychedelic-assisted pharmacotherapy: clinical applications and regulatory considerations.

After decades of regulatory marginalization, psychedelic compounds have reemerged as promising therapeutic tools in psychiatry, driven by unmet clinical needs in treatment-resistant mental disorders and by growing evidence of rapid and sustained effects on mood, cognition, and be...

Deciphering Ibogaine's Matrix Pharmacology: Multiple Transporter Modulation at Serotonin Synapses.

Ibogaine is the main psychoactive alkaloid produced by the iboga tree (Tabernanthe iboga) that has a unique therapeutic potential across multiple indications, including opioid dependence, substance use disorders, depression, anxiety, posttraumatic stress disorder (PTSD), and trau...

Mystical experiences during magnesium-Ibogaine are associated with improvements in PTSD symptoms in veterans.

Ibogaine is an atypical psychedelic that evokes unique subjective effects, including mystical experiences. Mystical experiences have shown a mediating effect on clinical improvements following treatment with several psychedelic substances; however, the relationship between mystic...

Psychedelics, entactogens and psychoplastogens for depression and related disorders.

Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N-dimethyltryptamine, ayahuasca; non-hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplas...

Ibogaine: Revisiting an Ancient Alkaloid for Modern Opioid Dependence.

Ibogaine is a naturally occurring hallucinogenic alkaloid originally used in ritualistic ceremonies by West Central African tribes for centuries. Ibogaine's rise in popularity in the 1960s was fueled by reports from those with a heroin addiction that claimed ibogaine stemmed thei...

Ibogaine for Opioid Use Disorder: An Unrecognized Risk.

The psychedelic substance, ibogaine, has garnered growing interest among policymakers, researchers, and the public in its potential use for opioid use disorder (OUD). Many states are allocating significant funds to investigate it further. However, some proponents of ibogaine are ...

Opioid agonist treatment outcomes among individuals with a history of nonfatal overdose: Findings from a pragmatic, pan-Canadian, randomized control trial.

History of nonfatal overdose (NFO) is common among people who use opioids, but little is known about opioid agonist treatment (OAT) outcomes for this high-risk subpopulation. The objective of this study was to investigate the relative effectiveness of buprenorphine/naloxone and m...

Opioid consumption frequency and its associations with potential life problems during opioid agonist treatment in individuals with prescription-type opioid use disorder: exploratory results

Traditional treatment approaches for prescription-type opioid use disorder (POUD), centered on abstinence, have limitations and hinder the development of interventions that meet the needs of people with POUD. Reduction in use without complete abstinence presents a promising avenu...

Association of driving with blood delta-9-tetrahydrocannabinol: a systematic review.

Driving under the influence of cannabis increases the risk of motor vehicle collisions. In some jurisdictions, deterrence rests on the ability to detect delta-9-tetrahydrocannabinol (THC) in blood. Recent evidence suggests that there may be a nuanced relationship of blood THC to ...

Total alkaloids of Bulbus Fritillariae Pallidiflorae alleviated silica induced pulmonary inflammation and fibrosis via regulating EMT and TGF-β1/Smad signaling pathway.

Silicosis is an interstitial lung disease caused by long-term exposure to an environment containing silica, characterized primarily by chronic inflammation and progressive fibrosis. Due to its complex pathogenesis, lung transplantation is the only curative treatment. Therefore, t...

Noribogaine altered intrinsic properties of thalamocortical neurons in a sex-dependent manner.

Noribogaine (Noribo) is the primary metabolite from ibogaine, an atypical psychedelic. The main objective of this study was to evaluate the effect of Noribo on thalamic physiology of calcium channels voltage activation and gene expression and the potential involvement of the 5-HT...

The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials.

Background and Objectives: Substance use disorders (SUDs) affect millions worldwide. Despite increasing drug use, treatment options remain limited. Psychedelic-assisted therapy (PAT), integrating psychedelic substances with psychotherapy, offers a promising alternative by address...

Use of Psychedelic Agents in Older Adults with Treatment-Resistant Major Depressive Disorder: What the Evidence Shows.

The use of drugs with psychedelic and dissociative effects for the treatment of psychiatric illnesses has become increasingly popular in recent years. However, few trials have been conducted to determine the efficacy of these agents in the specific setting of treatment-resistant ...

Modification of natural tryptamines for the treatment of neuropsychiatric diseases.

The last decade represented a period of unprecedented interest in, and development of, traditional psychedelic substances for the treatment of a variety of neuropsychiatric disorders. While early clinical trials of classical psychedelics, several of the major ones being tryptamin...

Psychedelic Augmentation of 12-Step Engagement: A Novel, Accessible Approach to Enhance Community-Based Recovery from Substance Use Disorders.

Amid an evolving psychedelic drug policy landscape and limitations of existing substance use disorder (SUD) treatments, a novel addiction recovery paradigm has emerged involving augmentation of 12-Step program engagement with therapeutic psychedelic use. A preliminary qualitative...